Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKGM42)

Drug Name
BREQUINAR Drug Info
Synonyms
Brequinar; 96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [1]
Acute myeloid leukaemia 2A60 Phase 1/2 [2]
Cross-matching ID
PubChem CID
57030
CAS Number
CAS 96187-53-0
TTD Drug ID
DMKGM42

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dihydroorotate dehydrogenase (DHODH)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [4]
Vidofludimus DM0POWG Inflammatory bowel disease DD72 Phase 2 [5]
BAY2402234 DMRL6W5 Myeloid leukaemia 2B33.1 Phase 1 [6]
LAS-186323 DMV80DP Multiple sclerosis 8A40 Phase 1 [7]
HR325 DM51GZS Rheumatoid arthritis FA20 Discontinued in Phase 2 [8]
FK778 DMH6QAI Kidney/heart transplant rejection NE84 Discontinued in Phase 2 [9]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dihydroorotate dehydrogenase (DHODH) TTLVP78 PYRD_HUMAN Modulator [3]

References

1 ClinicalTrials.gov (NCT04575038) CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 (CRISIS2). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03760666) A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
3 DOI: 10.1203/00006450-198807000-00137
4 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5 Company report (4SC)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of Aslanpharma.
8 In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine. Scand J Immunol. 2002 Jul;56(1):35-42.
9 Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model. Transplantation. 2003 Dec 15;76(11):1627-9.